The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias

The role of tumour–stromal interactions in modifying drug response: challenges and opportunities

(2013) Douglas W. McMillin et al.   NATURE REVIEWS DRUG DISCOVERY

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications

(2011) J. Jakubikova et al.   BLOOD

Future Directions of Next-Generation Novel Therapies, Combination Approaches, and the Development of Personalized Medicine in Myeloma

(2011) Constantine S. Mitsiades et al.   JOURNAL OF CLINICAL ONCOLOGY

Microenvironmental Influence on Pre-Clinical Activity of Polo-Like Kinase Inhibition in Multiple Myeloma: Implications for Clinical Translation

(2011) Douglas W. McMillin et al.   PLoS One

Increased ABCB1 Expression in TP-110-Resistant RPMI-8226 Cells

(2010) Masatomi IIJIMA et al.   BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY

Proteasome inhibitor MG132 reverses multidrug resistance of gastric cancer through enhancing apoptosis and inhibiting P-gp

(2010) Yafei Zhang et al.   CANCER BIOLOGY & THERAPY

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity

(2010) Douglas W McMillin et al.   NATURE MEDICINE

Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235

(2009) D. W. McMillin et al.   CANCER RESEARCH

Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib

(2009) M. G. Ooi et al.   CLINICAL CANCER RESEARCH

Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma

(2009) Lia E. Perez et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02

(2009) S. LÜ et al.   International Journal of Laboratory Hematology

Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines

(2009) D. M. Collins et al.   INVESTIGATIONAL NEW DRUGS

PI3K/Akt inhibition modulates multidrug resistance and activates NF-κB in murine lymphoma cell lines

(2008) Mariana G. García et al.   LEUKEMIA RESEARCH

In vitro activity of bortezomib in cultures of patient tumour cells—potential utility in haematological malignancies

(2008) Kristina Wiberg et al.   MEDICAL ONCOLOGY